MAVYRET™ (glecaprevir + pibrentasvir)

































  • PRS = Prior treatment with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir
  • In trials, prior NS5A inhibitor treatment included ledipasvir and daclatasvir
  • In trials, prior NS3/4A PI treatment included simeprevir, boceprevir, or telaprevir
HCV GN Previous treatment No cirrhosis Child-Pugh A
1 An NS5A inhibitor without prior treatment with an NS3/4A protease inhibitor 16 weeks 16 weeks
1 An NS3/4A protease inhibitor without prior treatment with an NS5A inhibitor 12 weeks 12 weeks
1, 2, 4, 5, 6 PRS 8 weeks 12 weeks
3 PRS 16 weeks 16 weeks

  • PRS = Prior treatment with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir
  • In trials, prior NS5A inhibitor treatment included ledipasvir and daclatasvir
  • In trials, prior NS3/4A PI treatment included simeprevir, boceprevir, or telaprevir
HCV GN Previous treatment Duration
1, 2, 3, 4, 5, 6 None 12 weeks
1 NS5A inhibitor-experienced without prior treatment with an NS3/4A protease inhibitor 16 weeks
3 PRS treatment-experienced 16 weeks